{"id":"W2121072773","doi":"10.1093/eurheartj/sui016","title":"Emerging therapies for stroke prevention in atrial fibrillation","year":2005,"lang":"en","type":"article","venue":"European Heart Journal Supplements","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"Government of Canada; Heart and Stroke Foundation of Canada; AstraZeneca","keywords":"Medicine; Antithrombotic; Ximelagatran; Stroke (engine); Atrial fibrillation; Contraindication; Aspirin; Clinical trial; Intensive care medicine; Fibrinolytic agent; Cardiology; Internal medicine; Warfarin; Dabigatran; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001272903,0.0004059864,0.0005721868,0.0007943393,0.0003189228,0.0008082638,0.0004217574,0.0009692767,0.009735879],"category_scores_gemma":[0.001844954,0.00007821769,0.0004572869,0.000561888,0.0003701338,0.001038849,0.0006466355,0.001898681,0.001878063],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000343693,"about_ca_system_score_gemma":0.00078941,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003353896,"about_ca_topic_score_gemma":0.001302793,"domain_scores_codex":[0.9995151,0.0002220242,0.00004765229,0.00002894282,0.0001619275,0.00002444889],"domain_scores_gemma":[0.9991336,0.0003910375,0.00009554459,0.00003821753,0.0002509934,0.00009067625],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001555847,0.0002723213,0.0006905414,0.002982405,0.00007275151,0.0004334973,0.0001527599,0.0001133651,0.001346717,0.0165018,0.05237932,0.9248989],"study_design_scores_gemma":[0.0002268038,0.0006185455,0.002257503,0.003451582,0.0001552715,0.001735323,0.0001986494,0.0002178675,0.0005747334,0.01841487,0.9721362,0.00001274719],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002632936,0.918233,0.002887904,0.03597499,0.005720849,0.00006531608,0.00009694218,0.0000534992,0.0343345],"genre_scores_gemma":[0.01841269,0.936939,0.01228858,0.01310669,0.007977982,0.0001441949,0.0001797421,0.00001613644,0.01093504],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.009735879,"threshold_uncertainty_score":0.03256977,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09123812633891777,"score_gpt":0.3928723977566679,"score_spread":0.3016342714177502,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}